FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma

Phase 1

Terminated

Conditions: Colorectal Adenocarcinoma

Interventions: Drug: Quinacrine and Capecitabine

First Posted Date: 2013-05-01

Last Posted Date: 2021-03-25

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 19

Registration Number: NCT01844076

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer

Not Applicable

Completed

Conditions: Stage IB Non-small Cell Lung Cancer
Stage IIA Non-small Cell Lung Cancer
Stage IIB Non-small Cell Lung Cancer
Stage IA Non-small Cell Lung Cancer

Interventions: Procedure: breath test
Other: laboratory biomarker analysis

First Posted Date: 2013-04-25

Last Posted Date: 2023-03-13

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 41

Registration Number: NCT01840150

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery

Phase 1

Terminated

Conditions: Acinar Cell Adenocarcinoma of the Pancreas
Stage IIB Pancreatic Cancer
Duct Cell Adenocarcinoma of the Pancreas
Stage III Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Radiation: hyperfractionated radiation therapy
Radiation: intensity-modulated radiation therapy
Radiation: radiosurgery
Procedure: diffusion-weighted magnetic resonance imaging

First Posted Date: 2012-12-03

Last Posted Date: 2019-07-29

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 6

Registration Number: NCT01739439

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care

Not Applicable

Completed

Conditions: Signet Ring Adenocarcinoma of the Colon
Stage IIB Colon Cancer
Stage IIC Colon Cancer
Stage IIC Rectal Cancer
Stage IIIA Colon Cancer
Stage IB Non-small Cell Lung Cancer
Stage IIB Non-small Cell Lung Cancer
Stage IIB Rectal Cancer
Stage IIIB Colon Cancer
Stage IIIB Rectal Cancer

Interventions: Other: educational intervention
Other: medical chart review

First Posted Date: 2012-11-14

Last Posted Date: 2017-04-06

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 1440

Registration Number: NCT01726296

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer

Phase 1

Completed

Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Recurrent Basal Cell Carcinoma of the Lip
Recurrent Colon Cancer
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
Recurrent Lymphoepithelioma of the Nasopharynx
Recurrent Lymphoepithelioma of the Oropharynx
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
Recurrent Mucoepidermoid Carcinoma of the Oral Cavity

Interventions: Drug: everolimus
Biological: cetuximab
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2012-07-11

Last Posted Date: 2012-07-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 12

Registration Number: NCT01637194

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Phase 2

Terminated

Conditions: Stage II Bladder Cancer
Stage III Bladder Cancer
Proximal Urethral Cancer
Squamous Cell Carcinoma of the Bladder
Distal Urethral Cancer
Urethral Cancer Associated With Invasive Bladder Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: cisplatin
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2012-06-05

Last Posted Date: 2019-07-29

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 32

Registration Number: NCT01611662

Locations: 🇺🇸
Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Facilitating Follow-Up Adherence for Abnormal Pap Smears

Not Applicable

Completed

Conditions: Uterine Cervical Neoplasms

Interventions: Behavioral: Cognitive-affective barriers counseling
Behavioral: Cognitive-affective barriers counseling via brochure
Behavioral: standard care

First Posted Date: 2012-03-23

Last Posted Date: 2012-03-23

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 211

Registration Number: NCT01561326

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

Phase 2

Withdrawn

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma
Stage I Adult Diffuse Large Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2012-02-27

Last Posted Date: 2016-03-03

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT01539174

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer Recurrent
Non-small Cell Lung Cancer Metastatic

Interventions: Drug: MLN8237 and Erlotinib

First Posted Date: 2011-11-16

Last Posted Date: 2018-05-17

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 22

Registration Number: NCT01471964

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Procedure: quality-of-life assessment
Radiation: intensity-modulated radiation therapy
Radiation: 3-dimensional conformal radiation therapy

First Posted Date: 2011-11-11

Last Posted Date: 2020-05-08

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 24

Registration Number: NCT01470365

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy